stockportfolio.pro
TransMedics Group, Inc. (TMDX)
Healthcare · Medical Devices · NasdaqGM
TransMedics Group, Inc. revenue & earnings — last 8 fiscal years
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $13.02M | $23.60M | $25.64M | $30.26M | $93.46M | $241.62M | $441.54M | $605.49M |
| Gross profit | $5.73M | $13.86M | $16.64M | $21.16M | $65.27M | $154.09M | $262.08M | $362.81M |
| Net income | $-23.76M | $-33.55M | $-28.75M | $-44.22M | $-36.23M | $-25.03M | $35.46M | $190.29M |
| Net margin | -182.5% | -142.1% | -112.1% | -146.1% | -38.8% | -10.4% | 8.0% | 31.4% |
Source: TransMedics Group, Inc. SEC filings (10-K).
Explore 8 years of TransMedics Group, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track TMDX in your portfolio →
About TransMedics Group, Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
TransMedics Group, Inc. — frequently asked questions
What is TransMedics Group, Inc.'s revenue?
TransMedics Group, Inc. (TMDX) reported revenue of $605.49M for fiscal year 2025, up 37.1% from the prior year, according to its SEC filings.
Is TransMedics Group, Inc. profitable?
Yes. TMDX earned net income of $190.29M in fiscal 2025, a net margin of 31.4%.
What is TMDX's P/E ratio?
TransMedics Group, Inc. trades at a price-to-earnings ratio of about 17.0 based on the latest data in our nightly-refreshed cache.
How fast is TransMedics Group, Inc. growing?
TMDX's revenue grew at roughly 88.2% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from TransMedics Group, Inc.'s official SEC filings (10-K and 10-Q), covering 8 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.